Interleukin 2 (IL-2) and B-cell growth factors I and II (BCGF I and BCGF II) are lymphokines produced by T cells that play a major role in T-and B-cell cooperation.
going intermittent hemodialysis were tested for their capacity to produce IL-2 and BCGFs and to respond to these soluble mediators. IL-2 and BCGF activities were determined by means of two biological assays (proliferation of IL-2-dependent cytotoxic T-celt line CTLL-2 and of anti-human IgM (ja chain)-stimulated normal B cells, respectively) in the supernatants of phytohemagglutinin A-stimulated T-cell cultures. IL-2 activity was significantly decreased in patients as compared to normal controls (mean ± SEM, 0.28 ± 0.09 unit per ml) in hemodialyzed patients versus 1.02 ± 0.16 units per ml in normal controls). This profound abnormality contrasted with the normal activity of the BCGFs that was invariably observed in the same supernatants. A similar dissociation was detected when analyzing the sensitivity of uremic B and T cells to exogenous purified lymphokines. Anti-IgM (,u chain)-stimulated uremic B cells exhibited a normal response to recombinant IL-2 and to chromatography-purified BCGF I and BCGF II. Resting B cells Ad not show any increased reactivity to these lymphokines. In contrast, whereas in normal controls recombinant IL-2 exclusively induced the proliferation of T cells that had been previously activated by a mitogen, resting T cells from uremic patients were highly responsive to exogenous IL-2. This abnormal response was paralleled by significantly increased proportions of peripheral T cells recognized by the anti-Tac monoclonal antibody that specifically binds to the IL-2 receptor. These data clearly show the existence in hemodialyzed patients of abnormally high proportions of T cells presenting phenotypic and functional signs of preactivation. This increased T-cell IL-2 receptor expression may offer an explanation to the deficient IL-2 activity observed in patients' supernatants (by inducing increased absorption of the lymphokine). The potential relevance of these preactivated T cells to the depressed cell-mediated immunity observed in hemodialyzed patients is outlined.
Patients undergoing intermittent hemodialysis present a depressed in vivo and in vitro immune reactivity that is independent of their initial pathology (1) . The immunopathological basis of this immunosuppression is far from being entirely understood. Hemodialyzed patients show a decrease of absolute numbers of circulating lymphocytes, cutaneous anergy, prolonged survival of skin grafts (2, 3) , and abnormally low antibody responses to some (but not all) thymusdependent antigens like hepatitis B vaccine (4) . In contrast, a normal response against thymus-independent antigens like pneumococcal vaccine is generally observed. That all of these immune aberrations may not be simply ascribed to the lymphocytopenia is indicated by several reports showing that the purified lymphocytes from patients exhibit low in vitro responses to alloantigens and in some cases to mitogens (5) .
In this work, one of the main factors controlling the level of immune responses has been studied in hemodialyzed patients-that is the production and targeting of two major lymphokine activities involved in lymphocyte cooperation: interleukin 2 (IL-2) and B-cell growth factors (BCGFs). These soluble mediators are produced by lymphocytes following antigenic or mitogenic stimulation and promote the proliferation and/or the differentiation of functionally distinct T-and B-lymphocyte subsets (6) (7) (8) . In addition to evaluations of IL-2 and BCGF synthesis by T cells from patients, the response of T and B lymphocytes to the exogenous purified or semipurified lymphokines (recombinant IL-2 and chromatography-purified BCGF I and BCGF II) was tested. Moreover, the anti-Tac monoclonal antibody was used to quantitate patients' circulating T cells that expressed the IL-2 receptor, which is considered an activation marker (9) . The results obtained show the existence in hemodialyzed patients of abnormally high proportions of circulating T cells presenting phenotypic and functional signs of preactivation. The potential immunopathological significance of this observation will be outlined.
PATIENTS AND METHODS
Patients. Twelve adult patients (six men and six women), stabilized on renal replacement therapy (at least 3 months of intermittent hemodialysis treatment prior to the study) were selected for the study. They ranged in age from 28 and 64 years (mean, 40.5 ± 3.8). In these patients, chronic renal failure was due to chronic glomerulonephritis ( LGL, large granular lymphocytes.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. against hepatitis B virus; only one of them developed protective antibody titers (HAD), whereas the other three (TUR, CHA, and DAM) showed no response. All patients were negative by Elisa for human immunodeficiency virus HIV. All blood samples were collected before dialysis and twice at 1-month intervals to test the reproducibility of the assays used. Control samples were obtained from 27 age-and sex-matched healthy subjects. Cellular Preparations. Peripheral blood mononuclear cells (PBM) were isolated by centrifugation at 400 x g on a Ficoll-Paque (Pharmacia, Uppsala, Sweden) gradient. PBM were recovered at the interface and washed twice in Hanks' balanced salt solution (Eurobio, Paris, France). When required, PBM were separated into T cells and non-T-cells by rosetting with neuraminidase (Behringwerke)-treated sheep erythrocytes (SRBC). The rosetting erythrocyte E+ cells thus obtained contained 92-95% OKT3' T cells, and the nonrosetting E-non-T-cell population contained 2-5% OKT3' cells, as assessed by indirect immunofluorescence (described below).
When needed, B lymphocytes contained in the E-population were purified by means of an additional E-rosetting procedure, adherence to plastic to partially eliminate contaminating monocytes (1 hr of incubation on culture Petri dishes), and finally treatment with the Leu-1 monoclonal antibody (Becton-Dickinson) and rabbit complement. These preparations (referred to as enriched B cells) contained 80-85% surface Ig-expressing cells, 5-10% peroxidase-positive cells, and <0.5% Leu-l and/or OKT3' cells. When cultured in the presence of mitogenic phytohemagglutinin (PHA) concentrations, these preparations were unable to proliferate. Furthermore, after a 4-day stimulation with PHA or growth factors, this B-cell-enriched population still showed <0.5% Leu-1 and/or OKT3' cells.
Immunofluorescence Test. Indirect immunofluorescence was performed on PBM, E+, and E-cells with the monoclonal antibodies UCHT1 (given by P. Beverley), OKT3, OKT4, and OKT8 (Ortho Pharmaceutical) that respectively react with peripheral mature human T cells, helper/inducer T cells, and cytotoxic/suppressor T cells (10) . In some patients, the anti-Tac monoclonal antibody (given by T. Waldmann), which specifically recognizes the IL-2 receptor, was used (9) . Similarly, in some experiments the monoclonal antibody 3B8, which recognizes human large granular lymphocytes (LGL), was used (11) . The indirect immunofluorescence technique has been described in detail (12) . Briefly, the cells (10-20 x 106 per ml) were incubated at 4°C with appropriate dilutions of OKT3, OKT4, OKT8, anti-Tac, or 3B8 antibodies. After two washes in cold Hanks' balanced salt solution containing 5% fetal calf serum and 0.2% sodium azide, the cells were labeled for 30 min at 4°C with fluorescein-conjugated goat anti-mouse IgG antiserum (Nordic, Tilburg, The Netherlands). Following a washing procedure and resuspension, one drop was examined under Leitz Dialux microscope equipped for epifluorescence, and 200 cells per slide were counted. The percentage of each T-cell subset with respect to the total number of mononuclear cells counted was then calculated, and the percent OKT4/percent OKT8 cell ratio was evaluated. When necessary, the absolute counts of each separate T-cell subset were deduced by taking into account the total lymphocyte counts.
Lymphokine Production. Culture medium was RPMI 1640 (GIBCO) supplemented with penicillin (100 units per ml), streptomycin (100 ,ug/ml), and fetal calf serum (2%). E+ cells were adjusted to 1 x 106 cells per ml and distributed (1 ml/well) in 24-well Limbro culture plates (GIBCO). They were then stimulated with 0.4 jig or 4 Ag of PHA-P (Pharmacia) per ml. Supernatants were collected after 48 hr of culture (in humidified 95% air/5% CO2 at 370C), centrifuged, sterilized by filtration (45-gm pore size); und stored at -20'C until tested for IL-2 and BCGF activity.
IL-2 Titration. Culture supernatants were thawed and tested for their IL-2 activities on the IL-2-dependent murine cytotoxic T-cell line CTLL-2. Briefly 4 x 103 cells were cultured in round-bottom microplates in the presence of serial dilutions of the test supernatants. The proliferation was analyzed after 74 hr by means of a 4-hr [3H]thymidine (CEA, Gif-sur-Yvette, France) incorporation assay. Units were calculated by comparison with the mitogenic activity of serial dilutions of a reference supernatant containing by definition 1 unit per ml (produced by 48 hr ofPHA stimulation of normal PBM) (13) . The unit concentration of each supernatant was calculated by using a probit program.
Sensitivity of T Cells to Exogenous IL-2. Non-stimulated T cells. Freshly isolated E-rosetting T cells were cultured (0.5 x 106 per ml) in round-bottom microtiter culture plates (0. The same sort of B-cell proliferating assay first described was used. Enriched B-cell populations ofpatients and controls were tested. Semipurified BCGF I was purchased from Cellular Products (Buffalo, New York) and used at 10% (vol/vol) final concentration. BCGF II (or 50-kDa BCGF) was obtained as described (14) after lectin (concanavalin A) chromatography and was used at 10% (vol/vol) final concentration. Recombinant IL-2 was used at a final concentration of 1 unit per ml.
Statistical Analysis. Statistical comparison of mean values was performed by using Student's "t" test.
RESULTS
Distribution of Peripheral Regulatory T-Cell Subsets. The percentage values of total T cells, helper/inducer T cells, and cytotoxic/suppressor T cells were analyzed by labeling PBM from hemodialyzed patients and normal controls with OKT3, OKT4, and OKT8 monoclonal antibodies. When data were expressed as the OKT4/OKT8 ratio (Fig. 1) , no consistent abnormalities inmthe relative proportions of the main regulatory T-cell subsets was noted in hemodialyzed patients. In all patients the test was performed twice at 1-month intervals with minimal variations in the results obtained. However, when the absolute counts of each separate subset were considered, one observed significantly lower values in patients as compared to control subjects (Table 1) , reflecting the lymphocytopenia present in these patients (the mean ± SEM of lymphocytes per mm3 in patients was 1364 ± 476 and in controls was 1950 + 430).
Lymphokine Activities. The biological activities of lymphokines IL-2 and the BCGFs were evaluated in parallel in the supernatants from stimulated E-rosetting T-cell cultures. Semipurified E-rosetting T cells were used instead of total mononuclear cells to eliminate the bias caused by the variable number of monocytes that usually contaminate lymphocyte suspensions from hemodialyzed patients. Here again, the test was performed twice, at 1-month intervals, with good consistency in the results.
11-2 activity. In 9 ofthe 12 patients studied, the IL-2 activity was either undetectable or close to background levels ( Table  2) . Only 3 patients showed significant IL-2 levels: 1 of them (MAG) presented a normal IL-2 activity, whereas the other 2 (JMA and SAM) exhibited depressed IL-2 values as compared to normal controls, although notably higher than the activity of the other patients.
To exclude the possibility that the observed defect was due to an abnormal refractoriness of patients' lymphocytes to the mitogenic stimulus, in seven cases, lymphocytes were cultured with supramitogenic concentrations of PHA (4 /Ag/ml).
Although IL-2 activity increased when using higher concentrations of the mitogen, it always remained lower in hemodialyzed patients when compared to control subjects (Table 3) . It also was verified that no excessive prostaglandin E2 production by remnant monocytes present in the culture was inhibiting IL-2 synthesis [monocytes can depress IL-2 production by releasing prostaglandin E2, which in turn activates specific suppressor T lymphocytes (15) ]. Prostaglandin E2 levels in culture supernatants were measured by means of a biological assay (16 significant capacity to proliferate in the presence of exogenous IL-2 independently of any prior stimulation (Fig.  2) . These results were corroborated by immunofluorescence labeling with the anti-Tac monoclonal antibody, which specifically reacts with the human IL-2 receptor. As shown in Fig. 2 , the proportion of Tac' cells was significantly higher in hemodialyzed patients than in normal controls. The T-cell nature of these Tac' cells has been confirmed by doublelabeling experiments. First, the monoclonal antibodies UCHT1 (murine IgGl) and anti-Tac (murine IgG2a) were used in combination, thus showing that the Tac' lymphocytes were also UCHT1+ (data not shown). Second, the 3B8 monoclonal antibody, which specifically recognizes human
LGL, also has been tested in combination with the UCHT1 antibody (11) . In fact, a particular subset of lymphocytes has been described bearing both T-cell and LGL markers, which are able to proliferate in the presence of IL-2 (17). This particular cell subset expresses lymphocyte-activated killer (LAK) activity (17, 18) . In the hemodialyzed patients that were analyzed, cells expressing the 3B8' UCHT1+ phenotype were not detected among the E-rosetting population (data not shown). All these double-labeling experiments were performed on the E+ cells of patients both before and after in vitro culture with recombinant IL-2. Finally, the IL-2 receptor expression after PHA stimulation was comparable in hemodialyzed patients and normal controls (data not shown).
Sensitivity of Peripheral B Cells to BCGF I, BCGF II, and Recombinant IL-2. Peripheral B lymphocytes from hemodialyzed patients presented a normal response to exogenous lymphokines (Fig. 3) . BCGF I and recombinant IL-2 induced a moderate and dose-related proliferation of resting B cells and did costimulate with anti-IgM (,u chain) antibody. The stimulatory effect mediated by BCGF II was strictly dependent on the presence of anti-IgM (IL chain) antibody, both in patients and controls (Fig. 3) .
DISCUSSION
The aim of the present study was to analyze in parallel different phenotypic -and functional immune parameters in patients undergoing chronic hemodialysis. As already reported by others (19, 20) , the relative proportions of helper/inducer (OKT4+) and cytotoxic/suppressor (OKT8+) T cells were found to be normal in these patients. However, in accordance with previous reports (15, 16) and in line with the lymphocytopenia commonly observed in chronic uremia, significantly lower absolute counts of both regulatory lymphocyte subsets were observed as compared to normal controls.
In parallel, we analyzed the production by patients' lymphocytes of two soluble mediators playing a central role in Tand B-cell cooperation-namely, IL-2 and the BCGFs-and the response of the T and B cells of patients to these lymphokines.
Human IL-2, formerly termed T-cell growth factor, is a glycosylated protein (15-18 kDa) produced by lymphocytes after mitogenic or antigenic stimulation (6, 21) . IL-2 has been purified to homogeneity, and its gene has been cloned, making the protein available as recombinant material (22) . Originally, IL-2 was thought to act exclusively on T cells, but recent data have shown that it could also affect B cells (23, 24) . Other lymphokines distinct from IL-2 are present in the supernatants of stimulated peripheral blood lymphocytes that induce B-cell proliferation (7, 8) . The first BCGF that has been identified-namely, BCGF I-has a molecular mass of 14-18 kDa (25, 26) . Its T-cell origin has been confirmed by reports describing the establishment ofa human T-cell hybrid producing this lymphokine (27, 28) . Subsequently, an additional BCGF activity termed BCGF II was isolated from the 0 0O co Medical Sciences: Chatenoud et al. supernatants of stimulated human lymphocytes and had a molecular mass of -50 kDa (29, 30) . The data reported in this study reveal an important distinction between the activities of IL-2 and the BCGFs detected in the supernatants of mitogen-stimulated cell culture from hemodialyzed patients. BCGF activity was found to be normally produced by nearly all of the lymphocytes from patients tested, thus contrasting with the significantly decreased IL-2 activity (close to background levels) found in 80% of patients.
This difference was associated with the distinct reactivity of the lymphocytes from patients to the two lymphokines. B lymphocytes from patients, like normal B cells, were able to proliferate in the presence of partially purified BCGF I, BCGF II, or recombinant IL-2, provided an appropriate first-activation signal [e.g., anti-IgM (,u chain) antibody] was given. No proliferative response was induced on the B cells In fact, whereas IL-2 only induced the proliferation of normal purified T lymphocytes that had previously been activated by an antigen or a mitogen, the resting T lymphocytes from patients were highly responsive to exogenous recombinant IL-2. Taken together with the increased proportion of patient T cells recognized by the anti-Tac tnonoclonal antibody that selectively binds to the IL-2 receptor, these data indicate the existence of circulating preactivated T cells in hemodialyzed patients. The IL-2 binding sites present on T cells from patients are probably high-affinity receptors, since a proliferative response is elicited by IL-2 on these cells [high-and low-affinity receptors for IL-2 have been described (31); both of them are recognized by the anti-Tac monoclonal antibody, but only the former mediate proliferation]. The increased T-cell IL-2 receptor expression may account, at least in part, for the decreased IL-2 activity detected in patients' lymphocyte supernatants by provoking increased absorption of the lymphokine. At this point it is important to underline that no evidence has been found in the hemodialyzed patients studied so far for the presence of increased proportions of peripheral LGL cells expressing the T3 marker and able to respond to IL-2. This particular cell subset has been shown to mediate a nonspecific cytolytic activity (lymphocyte-activated killer activity) (17, 18) . In fact, no doubly-labeled cells were found among the E+ cell populations from patients analyzed (both before or after in vitro culture in presence of exogenous IL-2) when using an anti-T3 monoclonal antibody (UCHT1) in combination with the 3B8 antibody that specifically recognizes human LGL cells (16) .
It is interesting that Raska et al. (16) in their series of hemodialyzed patients did not find any increase in the proportions of circulating T cells expressing HLA-DR antigens (usually present on activated T cells). This discrepancy with our own findings underlines the interest of studying several activation markers in parallel. It will be important to compare the IL-2 receptor and HLA-DR antigen expression in the same patients and, if the discrepancy is confirmed, to investigate its significance. form in culture supernatants of stimulated T cells as well as in human sera. It will be of interest to know if hemodialyzed patients show an increased IL-2 receptor release that could interfere with regulatory processes. It also would be important to determine the functions and putative deleterious actions of the described preactivated cells. They could act by generating aberrant immune or even autoimmune responses or, alternatively, by suppressing immunity, providing then an explanation to the depressed cell-mediated reactivity observed in hemodialysis patients.
